Valneva (NASDAQ:VALN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $26.00 price target on the stock.

Separately, Guggenheim reduced their price target on Valneva from $18.00 to $17.00 and set a buy rating on the stock in a research report on Friday, March 22nd.

Valneva Price Performance

Valneva stock opened at $8.52 on Thursday. Valneva has a 12 month low of $6.58 and a 12 month high of $17.05. The stock’s 50 day moving average is $7.96 and its 200-day moving average is $9.01. The company has a current ratio of 2.64, a quick ratio of 2.22 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $593.33 million, a price-to-earnings ratio of -20.78 and a beta of 2.22.

Valneva (NASDAQ:VALN) last posted its earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.20 by ($0.70). Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The firm had revenue of $45.12 million during the quarter, compared to analyst estimates of $45.06 million. Equities research analysts expect that Valneva will post -0.28 EPS for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. boosted its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.